Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Medtronic
Mallinckrodt
Colorcon
Boehringer Ingelheim

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

ZIOPTAN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Zioptan patents expire, and what generic alternatives are available?

Zioptan is a drug marketed by Oak Pharms Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-nine patent family members in thirty countries.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tafluprost profile page.

Drug patent expirations by year for ZIOPTAN
Drug Prices for ZIOPTAN

See drug prices for ZIOPTAN

Recent Litigation for ZIOPTAN

Identify potential future generic entrants

District Court Litigation
Case NameDate
SANTEN PHARMACEUTICAL CO. LTD. v. MICRO LABS LIMITED2018-08-01
Santen Pharmaceutical Co., Ltd. v. Micro Labs Limited2016-05-13
Santen Pharmaceutical Co., Ltd. v. Sandoz Inc.2016-05-13

See all ZIOPTAN litigation

PTAB Litigation
PetitionerDate
Micro Labs Limited2017-05-12

See all ZIOPTAN litigation

Pharmacology for ZIOPTAN
Synonyms for ZIOPTAN
(Z)-isopropyl 7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxy cyclopentyl)hept-5-enoate
(Z)-isopropyl 7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate
1-methylethyl (5Z)-7-((1R,2R, 3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy -1-butenyl-3,5-dihydroxycyclopentyl)-5-heptenoate
1-methylethyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5- dihydroxycyclopentyl}hept-5-enoate
1O6WQ6T7G3
209860-87-7
5-Heptenoic acid, 7-((1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl)-3,5- dihydroxycyclopentyl)-, 1-methylethyl ester, (5Z)-
5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5Z)-
860T877
AFP-168
AFP-168;MK2452
AKOS025294885
AN-5815
C25H34F2O5
CHEBI:66899
CHEMBL1963683
CS-2817
D06274
DB08819
DE-085
DE-118
EX-A564
GTPL7451
HMS3649F04
HY-B0600
Isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate
isopropyl (Z)-7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate
isopropyl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxy-but-1-enyl]-3,5-dihydroxy-cyclopentyl]hept-5-enoate
J-502635
MK-2452
MK2452
MolPort-020-006-049
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-(phenoxy)but-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
RP17751
Saflutan
SCHEMBL1286148
SR-01000946707
SR-01000946707-1
Taflotan
Tafluprost
Tafluprost (JAN/USAN/INN)
Tafluprost [USAN:INN:BAN]
Tafluprost isopropyl ester
Tapros
Tapros|||Taflotan
UNII-1O6WQ6T7G3
WSNODXPBBALQOF-VEJSHDCNSA-N
X2642
ZINC13912394
Zioptan (TN)

US Patents and Regulatory Information for ZIOPTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes   See Pricing   See Pricing Y Y   See Pricing
Oak Pharms Inc ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes   See Pricing   See Pricing Y   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for ZIOPTAN
Drugname Dosage Strength RLD Date
➤ Subscribe Ophthalmic Solution 0.0015% ➤ Subscribe   See Pricing

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
Johnson and Johnson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.